Department of Medicine, University of Minnesota, Minneapolis, MN, United States of America.
Regions Hospital, St Paul, MN, United States of America.
Cardiovasc Revasc Med. 2022 Dec;45:3-8. doi: 10.1016/j.carrev.2022.08.009. Epub 2022 Aug 8.
Mixed reality head-mounted displays (MR-HMD) are a novel and emerging tool in healthcare. There is a paucity of data on the safety and efficacy of the use of MR-HMD in the cardiac catheterization laboratory (CCL). We sought to analyze and compare fluoroscopy time, procedure time, and complication rates with right heart catheterizations (RHCs) and coronary angiographies (CAs) performed with MR-HMD versus standard LCD medical displays.
This is a non-randomized trial that included patients who underwent RHC and CA with MR-HMD between August 2019 and January 2020. Their outcomes were compared to a control group during the same time period. The primary endpoints were procedure time, fluoroscopy time, and dose area product (DAP). The secondary endpoints were contrast volume and intra and postprocedural complications rate.
50 patients were enrolled in the trial, 33 had a RHC done, and 29 had a diagnostic CA performed. They were compared to 232 patients in the control group. The use of MR-HMD was associated with a significantly lower procedure time (20 min (IQR 14-30) vs. 25 min (IQR 18-36), p = 0.038). There were no significant differences in median fluoroscopy time (1.5 min (IQR 0.7-4.9) in the study group vs. 1.3 min (IQR 0.8-3.1), p = 0.84) or median DAP (165.4 mGy·cm (IQR 13-15,583) in the study group vs. 913 mGy·cm (IQR 24-6291), p = 0.17). There was no significant increase in intra- or post-procedure complications.
MR-HMD use is safe and feasible and may decrease procedure time in the CCL.
混合现实头戴式显示器（MR-HMD）是医疗保健领域中的一种新颖且新兴的工具。在心脏导管插入术实验室（CCL）中使用 MR-HMD 的安全性和有效性的数据很少。我们旨在分析和比较使用 MR-HMD 进行右心导管检查（RHC）和冠状动脉造影（CA）与使用标准液晶医疗显示器进行的 RHC 和 CA 的透视时间、手术时间和并发症发生率。
这是一项非随机试验，纳入了 2019 年 8 月至 2020 年 1 月期间使用 MR-HMD 进行 RHC 和 CA 的患者。将他们的结果与同期的对照组进行比较。主要终点是手术时间、透视时间和剂量面积乘积（DAP）。次要终点是对比剂体积和术中及术后并发症发生率。
该试验纳入了 50 例患者，其中 33 例行 RHC，29 例行诊断性 CA。他们与对照组的 232 例患者进行了比较。与对照组相比，使用 MR-HMD 与手术时间明显缩短（20 分钟（IQR 14-30）与 25 分钟（IQR 18-36），p=0.038）。透视时间中位数无显著差异（研究组 1.5 分钟（IQR 0.7-4.9）与对照组 1.3 分钟（IQR 0.8-3.1），p=0.84）或 DAP 中位数（研究组 165.4 mGy·cm（IQR 13-15,583）与对照组 913 mGy·cm（IQR 24-6291），p=0.17）。术中或术后并发症无明显增加。
MR-HMD 的使用是安全可行的，可能会缩短 CCL 中的手术时间。
